A Meta-Analysis on Outcomes of Zanidatamab Plus Chemotherapy in Patients with Advanced HER2-positive Gastroesophageal Adenocarcinoma.
Henrique Jin Son Kim, Murilo Lauria Freire Ribeiro, Leonardo Gil-Santana et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis pooled outcomes from three clinical trials involving 685 patients with advanced HER2-positive gastroesophageal adenocarcinoma treated first-line with zanidatamab plus chemotherapy, with or without tislelizumab. The reconstructed pooled median overall survival was 26.05 months (95% CI: 23.60-30.04), and pooled median progression-free survival was 12.61 months (95% CI: 11.05-14.60). The pooled objective response rate was 70% (95% CI, 67-74). Serious treatment-emergent adverse events occurred in 66% (95% CI, 50%-81%), indicating substantial toxicity alongside reported antitumour activity.
Key findings
- Pooled median overall survival was 26.05 months (95% CI: 23.60-30.04); pooled median progression-free survival was 12.61 months (95% CI: 11.05-14.60).
- The pooled objective response rate was 70% (95% CI, 67-74), and disease control rate was 96% (95% CI, 78-100).
- Serious treatment-emergent adverse events occurred in 66% (95% CI, 50%-81%); grade ≥ 3 treatment-related AEs occurred in 65% (95% CI, 58%-71%).
- Any-grade diarrhea occurred in 89% (95% CI, 75%-98%), and grade ≥ 3 diarrhea in 26% (95% CI, 19%-34%).
Why it matters
The pooled results suggest substantial response and disease control with first-line zanidatamab-based combinations in advanced HER2-positive disease, while also documenting frequent serious and treatment-related toxicity. These efficacy and safety estimates can inform interpretation of early clinical-trial evidence, but should be considered in light of the need for randomized studies to clarify the treatment’s activity and safety.
What to keep in mind
The meta-analysis included only three clinical trials, and the authors state that future randomized studies are needed to further assess activity and safety.